Intrinsic resistance to MAPK pathway inhibitor in cell lines with loss of NF1 expression has also been seen in melanoma [67] and glioblastoma [68], suggesting that there are additional biomarkers of MEK inhibitor sensitivity that require elucidation. The gene discussed is NF1; the disease is melanoma.